Mode
Text Size
Log in / Sign up

iron therapy

1 published article · Updated continuously

Clinical Trial Landscape

Clinical Trials of iron therapy

4 trials tracked of iron therapy: 4 in phase 3 or 4 and 4 with published results. The most-cited published study has 229 citations.

4Trials tracked
4Phase 3 & 4
0Recruiting
4With published results
Phase distribution
Phase 3 4
  1. Phase 3 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Dialysis (ASCEND-D) Completed · 229 cited
  2. Phase 3 Anemia Studies in Chronic Kidney Disease: Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor Daprodustat-Non-Dialysis (ASCEND-ND) Completed · 218 cited
  3. Phase 3 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat-in Incident Dialysis (ASCEND-ID) Completed · 73 cited
  4. Phase 3 Anemia Studies in Chronic Kidney Disease (CKD): Erythropoiesis Via a Novel Prolyl Hydroxylase Inhibitor (PHI) Daprodustat in Non-Dialysis Subjects Evaluating Hemoglobin (Hgb) and Quality of Life (ASCEND-NHQ) Completed · 49 cited

Showing the 4 most-cited and recently-updated of 4 trials. Browse the full registry →

Trial data sourced from ClinicalTrials.gov. Counts describe the research landscape and are not a treatment recommendation. Informational only — not medical advice.

HCP Mode — summaries include clinical detail, trial data, and statistical outcomes.
Patient Mode — summaries use plain language, avoiding clinical jargon.